Insight Sciences Adds 4D-MSPECT© to its FDA Approved Product Offerings
Insight Sciences, a biomedical imaging technology company, and the University of Michigan recently completed a license agreement that allows Insight Sciences to sell the FDA approved 4D-MSPECT Myocardial Perfusion and Function Imaging software package.
Traverse City, MI (PRWEB) August 27, 2004 -- Insight Sciences, a biomedical
imaging technology company, and the University of Michigan recently completed a
license agreement that allows Insight Sciences to sell the FDA approved
4D-MSPECT Myocardial Perfusion and Function Imaging software
package.
“This agreement exemplifies our commitment to providing the best
in tomographic imaging software and hardware capabilities,” states Declan
Cooper, CTO of Insight Sciences. “We chose 4D-MSPECT after an opportunity to
extensively test the software, and will bundle it with our mobile workstations
as a premier cardiac imaging and assessment package.”
The 4D-MSPECT
software application is used for SPECT and PET based imaging studies. The
software quantitatively analyzes tomographic (SPECT) cardiac nuclear medicine
perfusion (ungated or gated) and blood pool (gated) studies and provides
measurements in a user readable format. Such variables can be reported in
comparison to normal ranges or distributions.
Insight Sciences’ mobile
workstations, the MW-I™ series, provide the capabilities of a desktop in a
portable computer. The systems have upgradeable CPU’s and other configurable
components such as dual disk drives, 256 megabytes of video memory, and up to
two gigabytes of main memory.
Insight Sciences LLC, is a biomedical
technology company that provides innovative hardware and software solutions for
tomographic imaging within Radiology, Nuclear Medicine, Cardiology, clinical
imaging trials for drug development and medical research. Visit www.insightsciences.com">www.insightsciences.com for more
information.
CONTACT INFORMATION:
Declan Cooper,
CTO
800-837-3220
e-mail protected from spam bots
# # #
Source : http://www.prweb.com/releases/2004/8/prweb153318.htm